Narcolepsy affects around 3 million people globally, disrupting sleep and causing severe daytime fatigue. Current treatments manage symptoms but have side effects. Takeda Pharmaceutical is seeking approval for oveporexton, a new drug targeting narcolepsy’s root cause by restoring orexin levels. This approach could reduce reliance on multiple medications and improve patient outcomes.













